Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 13/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.49 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231699 | 1.00 | KCNA5 (0.91) | KCNA5ALDH1A1LMNATP53HPGD | |
| SCHEMBL12201016 | 0.95 | KCNA5 (1.00) | KCNA5ALDH1A1LMNATP53HPGD | |
| SCHEMBL14267603 | 0.95 | KCNA5 (1.00) | KCNA5ALDH1A1LMNATP53HPGD | |
| SCHEMBL14267648 | 0.95 | KCNA5 (1.00) | KCNA5ALDH1A1LMNATP53HPGD | |
| SCHEMBL14267594 | 0.92 | KCNA5 (1.00) | KCNA5ALDH1A1LMNATP53HPGD | |
| SCHEMBL5072759 | 0.89 | KCNA5 (0.79) | KCNA5ALDH1A1LMNATP53HPGD | |
| SCHEMBL14300958 | 0.89 | KCNA5 (0.79) | KCNA5ALDH1A1LMNATP53HPGD | |
| SCHEMBL12201448 | 0.89 | KCNA5 (0.75) | KCNA5ALDH1A1LMNAHPGDKCNK3 | |
| SCHEMBL14267604 | 0.88 | KCNA5 (0.86) | KCNA5ALDH1A1LMNATP53HPGD | |
| SCHEMBL12202088 | 0.87 | KCNA5 (0.72) | KCNA5ALDH1A1LMNAHPGDKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | claimed |
| EP-2012758-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | Sanofi-Aventis Deutschland GmbH (DE) | 2009-01-14 | — | — | EP | claimed |
| WO-2007124849-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | WO | claimed |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| EP-2012758-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | Sanofi-Aventis Deutschland GmbH (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124849-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | KCNN3, CACNA1I, KCNN1 | KCNA5 67/4885ALDH1A1 3470/4885LMNA 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.